Onconova Therapeutics (NASDAQ: ONTX) and Vitae Pharmaceuticals (NASDAQ:VTAE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.
Valuation and Earnings
This table compares Onconova Therapeutics and Vitae Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Onconova Therapeutics||$2.36 million||7.01||-$22.15 million||($2.35)||-0.71|
Vitae Pharmaceuticals has higher revenue, but lower earnings than Onconova Therapeutics. Vitae Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconova Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for Onconova Therapeutics and Vitae Pharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Onconova Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 376.19%. Vitae Pharmaceuticals has a consensus target price of $21.67, indicating a potential upside of 3.17%. Given Onconova Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Onconova Therapeutics is more favorable than Vitae Pharmaceuticals.
Insider & Institutional Ownership
26.8% of Onconova Therapeutics shares are held by institutional investors. Comparatively, 72.6% of Vitae Pharmaceuticals shares are held by institutional investors. 27.3% of Onconova Therapeutics shares are held by company insiders. Comparatively, 14.8% of Vitae Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Onconova Therapeutics has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Vitae Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
This table compares Onconova Therapeutics and Vitae Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Onconova Therapeutics beats Vitae Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Vitae Pharmaceuticals Company Profile
Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer’s disease, or Alzheimer’s. VTP-43742, the Company’s wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.
Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.